✓ Translated by DotMD AI Clinical Council Source: Asian Pacific journal of cancer prevention : APJCP • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #34837931 ↗

Phase III Randomized Trial: Evaluation of Mucosamin Effect on Treating Radiation Induced Oral Mucositis during and after Radiotherapy amongst Patients with Oral Cavity Squamous Cell Carcinoma (N = 80)

Original Paper Title: “Evaluation of Mucosamin Effect on Treating Radiation Induced Oral Mucositis during and after Radiotherapy amongst Patients with Oral Cavity Squamous Cell Carcinoma”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 80
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The results of this study showed that Mucosamin spray was able to significantly improved radiation-induced oral mucositis in patients with oral squamous cell carcinoma. .
  • Study Design & Sample: Phase III Randomized Trial published in Asian Pacific journal of cancer prevention : APJCP (N = 80 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Asian Pacific journal of cancer prevention : APJCP (2021), this phase iii randomized trial evaluating 80 human participants investigated: Oral mucositis is a serious complication radiation therapy for cancer. Key clinical takeaway: The results of this study showed that Mucosamin spray was able to significantly improved radiation-induced oral mucositis in patients with oral squamous cell carcinoma. .

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Asian Pacific journal of cancer prevention : APJCP, 2021-11-01; N = 80; Rigor 82/100): The results of this study showed that Mucosamin spray was able to significantly improved radiation-induced oral mucositis in patients with oral squamous cell carcinoma. .

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: zinc-cold-therapy-zinc-gluconate → Rx: ultra-zinc-cold-therapy-zincum-gluconicum → Rx: bio-combination-28-schuessler-salts → Condition: stomatitis → Condition: throat-cancer → Condition: thymus-cancer →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 34837931: Phase III Randomized Trial: Evaluation of Mucosamin Effect on Treating Radiation Induced Oral Mucositis during and after Radiotherapy amongst Patients with Oral Cavity Squamous Cell Carcinoma (N = 80)

3 of 3 Free Questions Remaining